Silybum marianum in treatment and prevention of hepatotoxicity
Phase 2
- Conditions
- Acute lymphoblastic leukemia.Acute lymphoblastic leukaemia
- Registration Number
- IRCT2014080717325N2
- Lead Sponsor
- Ardabil University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Children aged under 15 with a diagnosis of acute lymphoblastic leukemia undergoing induction therapy Exclusion criteria: Patients with liver diseases or diabetes
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduces hepatotoxicity of chemotherapy. Timepoint: In first visit, Day 28, Day 56. Method of measurement: Enzymatic.
- Secondary Outcome Measures
Name Time Method Fasting blood glucose. Timepoint: In first visit, Day 28, Day 56. Method of measurement: In first visit, Day 28, Day 56.;Side effects. Timepoint: In first visit, Day 28, Day 56. Method of measurement: In first visit, Day 28, Day 56.